Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation

Trial Profile

Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Oct 2016 Status changed from recruiting to completed.
    • 27 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 10 Sep 2013 Planned initiation date changed from 1 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top